Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119898 | 0.87 | GPR119 (0.36) | GPR119GPR183 | |
| SCHEMBL148647 | 0.82 | GPR119 (0.55) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL2371173 | 0.82 | GPR119 (0.64) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL1713319 | 0.82 | GPR119 (0.54) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL388551 | 0.81 | GPR119 (0.59) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL386891 | 0.81 | GPR119 (0.59) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL384915 | 0.81 | GPR119 (0.59) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL1713594 | 0.81 | GPR119 (0.47) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL1713600 | 0.81 | GPR119 (0.47) | GPR119GPR183KCNH2CYP3A4CYP2C19 | |
| SCHEMBL15109997 | 0.81 | GPR119 (0.51) | GPR119GPR183KCNH2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011128394-A1 | 3-SUBSTITUTED 5-(PYRROLIDINE-1-CARBONYL) PYRROLIDINE AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128394-A1 | 3-SUBSTITUTED 5-(PYRROLIDINE-1-CARBONYL) PYRROLIDINE AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| CN-102131778-A | Heterocyclic gpcr agonists | PROSIDION LTD | 2011-07-20 | — | — | CN | disclosed |
| EP-2328867-A1 | HETEROCYCLIC GPCR AGONISTS | Prosidion Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | GPR119 1/4885GPR183 48/4885KCNH2 2010/4885 |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | GPR119 1/4885GPR183 67/4885KCNH2 2784/4885 |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885GPR183 29/4885KCNH2 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.